FIELD: medicine.
SUBSTANCE: pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of Ab to IL-1α is administered to a patient. The group of inventions relates to a method for increasing longevity with cachexia.
EFFECT: application of monoclonal antibodies to IL-1α has an impact on cachexia symptoms, allowing to stop the dry weight loss process and to increases life expectancy of such patients.
10 cl, 1 dwg, 1 tbl, 5 ex
